Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pozen gains after positive PIII results for ulcer reducing aspirin, as partner search gains momentum

This article was originally published in Scrip

Executive Summary

Pozen saw its share price surge as much as 19% in early trading on 22 March before closing up 8.8%, or $0.42, to $5.22 after reporting positive top-line data from its Phase III pivotal trials for its novel gastrointestinal-friendly aspirin candidate PA32540. The news added $11.6 million to the company's value at $143.6 million. The company is developing PA32540 for the secondary prevention of cardiovascular disease in patients that are at risk for aspirin-associated GI complications.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts